US health agency reapproves GSK blood cancer drug after new trial
FDA gives go-ahead to UK drugmaker’s multiple myeloma treatment Blenrep
Related reading
GSK blood cancer drug reapproved by EU regulator
Blenrep had been removed from sale after a trial failed to show it was superior to other treatments
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
Merck splits operations to separate oncology from non-cancer drugs
Reshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment Keytruda
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands